Analysis of blood tumor markers for cancer diagnosis and treatment monitoring
Analysis of Circulating Tumor Markers in Blood
This study is testing whether a simple blood test can replace traditional tissue biopsies to help diagnose cancer and monitor how well treatments are working.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 992 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Montpellier and 1 other locations) |
| Trial ID | NCT04025541 on ClinicalTrials.gov |
What this trial studies
This study focuses on the analysis of circulating tumor markers found in the blood, aiming to replace traditional tissue biopsies with a simpler blood test known as liquid biopsy. It investigates the diagnostic, prognostic, and predictive potential of these biomarkers, particularly in response to various medical interventions such as chemotherapy and surgery. By utilizing small cohorts for different clinical situations, the study seeks to generate feasibility data and proof of concept, which could pave the way for larger studies in the future.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with invasive tumor pathology, whether confirmed or suspected.
Not a fit: Patients who are unable to maintain regular follow-up due to psychological, family, social, or geographical reasons may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive method for diagnosing and monitoring cancer treatment effectiveness.
How similar studies have performed: While the concept of liquid biopsies is gaining traction, this specific approach focusing on the kinetics of blood markers in response to clinical events is relatively novel and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage, 2. Man or woman ≥ 18 years, 3. Obtaining of the informed consent signed before any procedure of specific preselection on approval. Exclusion Criteria: 1. Private persons of freedom or under guardianship, 2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons, 3. Pregnant woman and/or breast-feeding, 4. Unaffiliated patient to Social Protection System,
Where this trial is running
Montpellier and 1 other locations
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle — Montpellier, France (Recruiting)
- Icm — Montpellier, France (Recruiting)
Study contacts
- Study coordinator: texier emmannuelle
- Email: emmanuelle.texier@icm.unicancer.fr
- Phone: 0467613102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.